Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-388 in overweight/obese adults and type 2 diabetes
NCT04838405Phase 1Completed
- Sponsor
- Carmot Therapeutics
- Start
- Apr 2021
- Primary completion
- Jun 2024
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of zilebesiran in obesity (4 arms), sponsored by Carmot Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 24 weeks. Started Apr 2021; status: completed.
02
Drugs
zilebesiran
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04838405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838405.